Rac, Your kidding right? Just pulling our leg to see who will bite. LOL, When the worm stops wiggling its dead. Yeah, news in 19hours to ;-)))
iambak, LOL,sorry the KERX board has him for now, god bless you all for saving us from the plague. So how would you describe your experience with our former resident JACK A?
Real Imbecile your back did you give up on the KERX board after they figured out that you are a Fraud and a Bona Fide Jack A
"This post now makes it clear why this poster has ALWAYS talked out of both sides of their mouth with enough of a bias toward promoting negativity and doubt." I think trusty got it right and the post is an identity grab and a fraud. designed to get people to sign up as part of the injured class.
aer u dump? phase 3 never last. Every stock is up on phase 3 then it goes down..then it takes a week to go back up..that's how is it in BIOTECH
Or is the lead in the suit....work it both ways....we are all here to make money....a business opportunity....I think AMPE will end up significantly higher down the road a bit.
This is a drug that is I've stated before as worth staying aware of. It is the only compound I know of with demonstrated normal, hyaline cartilage regeneration properties. Stem cells also work, albeit with additional trials needed to assure broad, repeatable efficacy. TPX-100 has just completed Phase II enrollment, so it's still a few years off as well. Hopefully Ampion will be in final approval stage by the time Phase III starts. Note restriction to bilateral OA.
"OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company completed subject enrollment and all scheduled dosing in its Phase 2 clinical study of TPX-100 in subjects with bilateral osteoarthritis (OA) of the knee. The Company initiated the study in early 2014 (Press Release on February 20, 2014). One hundred fifteen (115) subjects have completed all scheduled intra-articular injections. The last subject’s last visit of the clinical site is scheduled inApril 2016, and the study results are expected in mid-2016."
A class action based on unexpectedly good results from saline should be an interesting pursuit.